Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
Retrieved on:
Wednesday, November 8, 2023
INAF, Meal, Research, Trial of the century, Faculty, Fasting, Stomach, Peptide YY, Endocrine gland, Membrane protein, GIP, Human, Regulatory News Service, Université Laval, Hyperinsulinemia, Agonal respiration, PYY, Type 2 diabetes, Inflammation, Fibrinogen, Metabolism, Volunteering, Development, Glycated hemoglobin, Phase, Prediabetes, Food court, Lipid, Disease, Risk, Plant, Medicine, Research and development, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Medical school, Industrial Affairs Committee (Iceland), Partnership, Sensation, Blood, Nutrition, Hormone, CET, Safety, Insulin resistance, Overweight, Gastric inhibitory polypeptide, Glucose, Insulin, Pharmaceutical industry, Dietary supplement, Medical device, Animal feed
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
Key Points:
- Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
Dissemination of a French Regulatory News, transmitted by EQS Group. - The study confirms TOTUM•63's efficacy results, in particular the lasting reduction in glycated hemoglobin, one of the main markers of prediabetes and type 2 diabetes.
- It demonstrates TOTUM•63's multi-target mode of action in subjects at risk, improving the efficacy of energy metabolism, particularly after meals.
- Mode of action clinical results: TOTUM•63 regulates energy metabolism
In addition to the positive clinical efficacy studies already conducted, the mode of action study was carried out on 19 overweight or obese volunteers at risk of developing type 2 diabetes.